5A2-SC8
DC49907
Recommended because it shares a closely related research category or delivery context. Formulation and performance are product- and study-specific.
View product →| CAS No. | Not available |
| Chemical Name | BAMP-TK-12 |
| Synonyms | BAMP TK 12， BAMP-TK-12 |
| SMILES | CCCCCCCCCCCCOCCSC(C)(C)SCCOC(=O)CCNCCCN1CCN(CCCN(CCC(=O)OCCSC(C)(C)SCCOCCCCCCCCCCCC)CCC(=O)OCCSC(C)(C)SCCOCCCCCCCCCCCC)CC1 |
| Formula | C76H150O9N4S6 |
| M.Wt | 1456.41 |
| Purity | >95% by ELSD-HPLC |
| Storage | Pure form: −20 °C, 1 year; In solvent: −80 °C, 6 months; −20 °C, 1 month. Sealed and protected from light. |
| Shipping condition | Ships from Shanghai. Pure lipid is stable during ice-pack transport. |
| Publication | A Combinatorial Library of Biodegradable Lipid Nanoparticles Preferentially Deliver mRNA. DOI: 10.1002/adfm.202204947 |
Literature-reported formulation composition
| Component | Reported mass ratio (w/w) | Role |
|---|---|---|
| BAMP-TK-12 | 16 | Ionizable lipid |
| Cholesterol | 4 | Sterol |
| DOPE | 4 | Helper phospholipid |
| DSPE-PEG2000 | 1 | PEG lipid |
| Reported ratio sum | 25 | Original ratio retained |
Formulation calculator unavailable. A calculation is not enabled where component molecular weights or a fixed molar recipe are unverified. The 800:200:200:50 microgram inputs are 16:4:4:1 by mass, not mol%. The in vivo recipe lists three component names but four weights (4:1:1:2); it is not substituted here. Obtain and verify the complete composition and component molecular weights before planning component quantities.
Literature-reported performance for the cited formulation
Literature-reportedUp to 95%RFP mRNA, in vitro; separate from DUF5 mouse studies · 48 hMain PDF p.2 and Fig.2; Methods pp.8-9
Literature-reported9.27TNS assay; formulation-specificMain PDF p.3; SI Fig.S5
Literature Data DisclaimerAll formulation parameters and performance values shown in this section are derived from the cited publication and are provided for reference only. These results were obtained using the specific materials, formulation process, cargo, dose, analytical method, model and administration route described in that study. Unless otherwise stated, the data were not generated or independently verified by DC Chemicals. DC Chemicals supplies the lipid compound only and does not guarantee that customers will reproduce the reported LNP properties or biological performance.
The administration route shown above was used in the cited study and is not a clinical-use instruction or recommendation by DC Chemicals.
The administration route shown above was used in the cited study and is not a clinical-use instruction or recommendation by DC Chemicals.
Cited literature for this formulation and performance datasetA Combinatorial Library of Biodegradable Lipid Nanoparticles Preferentially Deliver mRNA. DOI: 10.1002/adfm.202204947 DOI: 10.1002/adfm.202204947
The 800:200:200:50 microgram inputs are 16:4:4:1 by mass, not mol%. The in vivo recipe lists three component names but four weights (4:1:1:2); it is not substituted here.
The 800:200:200:50 microgram inputs are 16:4:4:1 by mass, not mol%. The in vivo recipe lists three component names but four weights (4:1:1:2); it is not substituted here.